Comments
The board of JB Chemicals & Pharmaceuticals Ltd (JB Pharma) has approved the execution of a trademark license agreement with Novartis Innovative Therapies AG, Switzerland (contract worth ₹964 crore), for a portfolio of select ophthalmology brands, which will be effective in January 2027.
The board has also approved a promotion and distribution agreement with Novartis Healthcare Private Ltd for the same portfolio of select ophthalmology brands for the Indian market for three years starting December 2023.
JB Pharma stock traded at ₹1,473.85 on the BSE, up by 0.14 per cent as of 2:30 pm on Tuesday.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.